We're working on profiling this company soon. Let us know you're interested by sending us a request here »
We're working hard to bring you this company's profile. Register here to get an alert as soon we're done.
In the meantime, if you are interested in participating in placements on this stock click "Follow" on the toolbar above.
True to its history of reinvention and repurposing, Pharmaust will be renamed Neurizon Therapeutics...
Read ArticleASX closes higher with consumer and utilities leading the charge Wall Street rally boosts senti...
Read ArticleHealthcare stocks are doing relatively well globally in 2024 The sector could see more recovery as...
Read ArticleStockhead’s Sarah Hughan sits down with PharmAust (ASX:PAA) managing director Dr Michael Thurn to ge...
Read ArticleStockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of th...
Read ArticleBirth rates decline as people choose careers and pets Global pet industry is benefitting from this,...
Read ArticleAustralia’s clinical trials sector generated $1.6bn for the nation’s economy in 2022 according to M...
Read ArticleASX slips after hitting new high ahead of Fed decision Iron ore prices expected to drop below US...
Read ArticlePharmAust submits a request for orphan medicinal product designation to the EMA for monepantel to t...
Read ArticlePharmAust (ASX: PAA) has requested the European Medicines Agency (EMA) grant orphan medicinal produc...
Read ArticleASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing;...
Read ArticleMorgans has a Speculative Buy rating for PharmAust with a target price of 42c, up from 18c Monepant...
Read ArticleASX 200 down on Tuesday; energy and iron ore stocks rise BHP’s profit up 2pc, but dividend cut. Lov...
Read ArticleActinogen doubled on positive Phase 2a results for Xanamem Xanamem’s durability leads to a Phase 2b...
Read ArticlePharmAust (ASX: PAA) has received promising interim results from a major study into monepantel (MPL)...
Read ArticleS&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expec...
Read ArticleThe EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-l...
Read ArticleThe three months to end June marked a transformative quarter in PharmAust’s (ASX: PAA) focus on mone...
Read ArticlePharmAust (ASX: PAA) has raised $7.8 million in a share purchase plan (SPP) to accelerate developmen...
Read ArticleSpecial Report: PharmAust has achieved a major milestone after its lead investigational drug, monepa...
Read ArticlePharmAust’s (ASX: PAA) lead amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) treatmen...
Read ArticleASX health stocks fall 0.19% in past five days as broader markets lift 0.79% Morgans says capital r...
Read ArticleThe ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biot...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has been granted small and medium-sized en...
Read ArticleStockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episod...
Read ArticlePharmAust raises $10 million via institutional placement to progress pivotal trial Share price has...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has received strong market support for pla...
Read ArticleASX closes lower, but Energy sector blinks green Uranium mining stocks surged on Peter Dutton’s nuc...
Read ArticleThe success of PharmAust’s (ASX: PAA) Phase 1 MEND study into the treatment of motor neurone disease...
Read ArticleAussie stocks start the week flat; energy and tech sectors lead declines Investor caution prevails...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has appointed US-based Dr Katie MacFarlane...
Read ArticleASX health stocks fall in past five days in line with broader markets on mixed economic signals The...
Read ArticleAussie shares rise in arvo trade Resources sectors weigh, Real Estate adds 2pc GDP lowest in 40 yea...
Read ArticlePharmAust reports promising updates on MPL’s efficacy in treating MND/ALS New data suggests MPL sig...
Read ArticlePharmAust Limited (ASX: PAA) shares are catching the eye with a strong gain on Wednesday. At the tim...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has received positive survival benefit ass...
Read Article05 Jun 2024 - A snapshot of the stocks on the move, featuring Calmer Co International (ASX:CCO), Pha...
Read ArticleThe Calmer Co. International (ASX:CCO), a health and wellness company focussing on natural product...
Read ArticleStockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) pe...
Read ArticleS&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biot...
Read ArticleThe ASX200 is trading up around 0.55% With strong performances from major medical companies, the...
Read ArticlePharmAust reappoints Dr Michael Thurn as managing director and CEO to lead its push in human neurod...
Read ArticleFDA approves AVITA’s RECELL GO System Wound care medical company, AVITA Medical ASX:AVH), surged +13...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has strengthened its leadership team as it...
Read ArticleResearch shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase th...
Read ArticlePharmAust receives US FDA orphan drug designation for monepantel (MPL) to treat motor neurone disea...
Read ArticlePharmAust (ASX: PAA) has achieved a major breakthrough in plans to commercialise its monepantel (MPL...
Read ArticleTo register for today's webinar click here. PharmAust (ASX:PAA & PAAOA) announced it has recei...
Read Article17 May 2024 - A snapshot of the stocks on the move, featuring PharmAust (ASX:PAA), Impact Minerals (...
Read ArticleASX losses accelerate after sluggish retail sector updates Baby Bunting, Temple & Webster, JB...
Read ArticleThe surprise announcement by Dr Michael Thurn to resign as CEO of PharmAust (ASX: PAA) last month, l...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) is looking to build on the successful deve...
Read ArticleASX rallies, with all sectors rallying on Tuesday The RBA holds rate, but keeps door open for more...
Read ArticleASX Health sector was in correction territory in April Why is the health sector different from othe...
Read ArticlePharmAust (ASX: PAA) is preparing to undertake a number of key activities in its treatment developme...
Read ArticlePharmAust (ASX: PAA) is preparing to undertake a number of key activities in its treatment developme...
Read ArticleThere’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to c...
Read ArticleThe ASX200 closed .4 of a per cent up with IT and Health Care the locomotives of a sluggish steam en...
Read ArticleThe ASX extends its gains on Tuesday Tech stocks rallied ahead of US megacap earnings, while goldie...
Read ArticleThe ASX200 is trading up around half a per cent with Health Care and Real Estate leading the gains,...
Read ArticleThe ASX200 is trading up around half a per cent with Health Care and Real Estate leading the gains,...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has announced that chief executive officer...
Read ArticleClinical-stage biotechnology company, PharmAust (ASX:PAA), shares have fallen as much as 24 per cent...
Read ArticleThe ASX close higher as unemployment rate came in lower than expected Miners rally, led by BHP as...
Read ArticleDr Herbert Brinkman joins PharmAust as head of manufacturing, bringing over 30 years of pharmaceuti...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has strengthened its management team with...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has received approval from the human resea...
Read ArticleThe ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL Small Ca...
Read ArticleMorgans says economic challenges have been catalyst for innovation and resilience in ASX health sec...
Read ArticleLocal markets end lower on big bank sell-off Material gains offset by Telco’s and Financials Small...
Read ArticlePhase 1 MEND study outcomes for MND/ALS treatment now with FDA for review in support of PharmAust’s...
Read ArticleBiotechnology company PharmAust (ASX: PAA) has filed supplementary positive data from a Phase 1 MEND...
Read ArticleThe ASX is set to rise again today with futures up 0.28% near 8.30am AEDT. US markets had another...
Read ArticleLocal markets give up early gains then regains them, closing 0.22pc higher Consumer Discretionary...
Read ArticleIs it fanciful imagining how rich one could be if only they had invested in a particular ASX stock?...
Read ArticleASX health sector rises in line with broader markets in the past five days AdAlta reports positive...
Read ArticleASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essenti...
Read ArticleS&P/ASX 200 rose 0.8% in February with Large Cap S&P/ASX 50 underperforming Midcap and Smal...
Read ArticlePharmAust (ASX:PAA) has announced that it has met its primary safety and tolerability endpoi...
Read ArticleHighlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Re...
Read ArticleViking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on p...
Read ArticleMPL found to be safe and well tolerated by MND/ALS patients treated under PAA’s Phase 1 trial Drug...
Read ArticleA little-known small-cap stock has rocketed on Wednesday morning after coming out of a two-day trad...
Read ArticleA Phase 1 trial into the effects of lead candidate monepantel (MPL) on patients with motor neurone d...
Read ArticleLocal markets are lucky to close a smidgen higher IT and Healthcare sectors offset a 2pc loss for...
Read ArticleMomentum investing has been shown to be a successful strategy over the long term. The strategy essen...
Read ArticleLocal markets end flat like an old can of coke on the coffee table Sectors are mixed up. I’m mixe...
Read ArticlePharmAust engages globally renowned experts in MND/ALS to form a scientific advisory board (SAB) T...
Read ArticlePerth-based clinical-stage biotechnology company PharmAust (ASX: PAA) has pulled together a team of...
Read ArticleBiotech doesn’t need another pandemic for a resurgence – it’s made a strong comeback regardless. Sto...
Read ArticleThe ASX200 closed the day up about .7 of a per cent. Most sectors finished in the green, led by m...
Read ArticleASX adds 0.7pc to close out the week in a positive frame of mind IT and materials rise, thanks to...
Read ArticlePharmAust (ASX: PAA) has achieved another significant milestone along the path to gaining approval f...
Read ArticleASX200 ends 0.75pc lower after a long slog back from -1.5pc this morning. Industrial Sector only g...
Read ArticlePharmAust announces first patient dosed in 12-month OLE study for patients with MND/ALS All 12 pati...
Read ArticleBiotechnology company PharmAust (ASX: PAA) has dosed the first patient in an open-label extension (O...
Read ArticlePerth-headquartered clinical-stage biotechnology company, PharmAust (ASX: PAA), has hit another mile...
Read ArticleDrug developer, Pharmaust (ASX:PAA) announces all 12 patients are finished with its phase one MEND s...
Read ArticlePharmAust says progression of its programs show it is a strong contender to compete in rare disease...
Read ArticleXi and Biden set to agree on restricting fentanyl Fentanyl is a synthetic opioid responsible for t...
Read ArticleBiotechnology company PharmAust (ASX: PAA) has progressed its monepantel (MPL) clinical programs for...
Read ArticleNews relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD f...
Read ArticlePharmAust (ASX:PAA) has announced that all patients in Cohort 4 have completed dosing in its...
Read ArticleThe ASX200 has slipped more than .3 of a per cent in early trade. And that’s a performance that’s sl...
Read ArticlePharmAust (ASX:PAA) wraps up cohort four of its phase one MEND study using MPL at 10 mg/kg to treat...
Read ArticlePerth-headquartered clinical-stage biotechnology company PharmAust (ASX: PAA) has achieved a signifi...
Read ArticlePAA has finished does all patients in cohort 4 of its phase 1 study in MND/ALS Data from phase 1 ex...
Read ArticlePharmAust (ASX:PAA) has announced positive top-line data from its Phase 2 veterinary clinica...
Read ArticleStockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might h...
Read ArticleDetermination of a clinically safe and efficacious dosing regimen of monepantel (MPL) for the treat...
Read ArticlePharmAust (ASX: PAA) has confirmed positive top-line data from a Phase 2 veterinary clinical study o...
Read ArticleL’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supr...
Read ArticleThe FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergenc...
Read ArticleEarnings reports dominated headlines in August Despite solid results from ASX healthcare giants, th...
Read ArticleAustralian biotech has attracted US investments in the last five years Among ASX stocks to get fund...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleNew chief executive has experience executing clinical studies Dr Thurn was formerly part of the TG...
Read ArticlePharmAust (PAA) appoints Dr Michael Thurn as its newest CEO, effective September 1 The company re...
Read ArticleClinical-stage biotechnology company investigating unique treatments for both humans and animals Pha...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticlePharmAust’s Phase 1 trial of lead drug candidate MPL shows positive signs of slowing MND/ALS progre...
Read ArticlePharmAust (PAA) reveals its phase one trial using MPL for MND and ALS has slowed disease progression...
Read ArticleStockhead’s Top 10 at 11, published at ~10.30am each trading day, highlights the best (and worst) pe...
Read ArticleAn interim analysis of data from a Phase 1 clinical trial of PharmAust’s (ASX: PAA) lead drug candid...
Read ArticleBiotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two g...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticlePharmAust is inching ever closer towards a Phase-2 clinical trial of its lead drug candidate monepan...
Read ArticleThe end of pandemic and higher rates have subdued biotech market But there are signs now the sector...
Read ArticlePharmAust (PAA) appoints liquidators from Grant Thornton Australia to administer the creditor’s volu...
Read ArticlePharmAust (ASX:PAA) has completed its third cohort of six participants in the Phase 1/2 clin...
Read ArticlePharmAust continues to progress the use of its lead drug candidate monepantel (MPL) in motor neurone...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticlePharmAust continues to progress the Phase 2 trial of lead drug monepantel (MPL) in dogs with B-cell...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleASX dips 0.56% despite a solid kickstart first thing this morning InfoTech outperforms the market a...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticlePharmAust’s (PAA) patient, Louie the Beagle, surpasses one year of treatment with the company’s Mone...
Read ArticleImricor jumps 13pc after securing $30m in funding Singular Health signs a master distribution agree...
Read ArticlePharmAust (ASX:PAA) has provided an update on the pharmacodynamic data from the Phase 1/2 tr...
Read ArticlePharmAust (PAA) releases preliminary data from its phase 1/2 trial assessing monepantel in Motor Neu...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticlePharmAust (PAA) announces that all 12 patients in cohort three have received an initial escalated do...
Read ArticlePharmAust has announced that all 12 patients in Cohort 3 of its Phase-1/2 clinical trial of its lead...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleBrisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “gam...
Read ArticlePharmAust (ASX:PAA) has announced the commencement of Cohort 3 dosing in its current phase 1...
Read ArticleFollowing the recent promotion of patients in Cohort 1 to Cohort 3, individuals will now receive a l...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleSmall cap health stocks are not known to pay dividends But there’s a handful of such stocks on the...
Read ArticleS&P/ASX 200 closes up 1% – its best performance in about a week All sectors bar IT and Utiliti...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some of the strongest performing ASX stocks that might...
Read ArticlePharmAust could soon move patients in the first cohort of its clinical trial into the use of monepan...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleAnimal research shows mTOR inhibitor drugs could reverse the ageing process Studies also show that...
Read ArticlePharmAust continues to progress the first phase of the clinical trial for its lead drug monepantel t...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleAn independent study by NYSE-listed Catalent Pharma Solutions shows PharmAust’s (PAA) anti-cancer dr...
Read ArticleIndependent tests have shown PharmAust’s Monepantel (MPL) anti-cancer drug retains long-term shelf l...
Read ArticleThe ASX is set to fall on Wednesday after some gloomy earnings forecast on Wall Street Debt ceiling...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleResearch from the Olivia Newton-John Cancer Research Institute on PharmAust’s Monepantel (MPL) anti-...
Read ArticlePharmAust’s (PAA) anti-cancer drug Monepantel (MPL) is published in the Wiley peer-review journal af...
Read ArticleThe ASX will open flattish on Tuesday Crude prices rise another 2pc overnight The market awaits the...
Read ArticleStockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might...
Read ArticleStockhead’s In Case You Missed It highlights some of the strongest performing ASX stocks that might...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleInvestors continue to demonstrate their support for PharmAust with binding commitments received for...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleArtificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discove...
Read ArticleThe Phase 2 trial studying PharmAust’s lead drug monepantel (MPL) in dogs with B-cell lymphoma is ex...
Read ArticlePharmAust (PAA) continues to report disease response in dogs with cancer treated by the company in a...
Read ArticleThe ASX is set to open lower on Friday, tracking Wall Street Tesla fell the most since January afte...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticleStockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have sl...
Read ArticlePharmAust has received additional MPL tablets to ensure it has enough availability for its Phase 1/2...
Read ArticleThe ASX is set to rise despite a modest selloff on Wall Street Earnings season begins in the US whe...
Read ArticleThe materials sector took a tumble in early trade, despite plenty of news among the miners. Great...
Read ArticlePharmAust’s deep pipeline of clinical trials on lead drug Monepantel means that a new CEO with stron...
Read ArticlePharmAust (PAA) begins an international search for a new CEO as the company progresses to more advan...
Read ArticleWall Street fell after report shows US inflation cooled in March US plans to increase EV car sales...
Read ArticleBiotechnology player PharmAust has completed enrolment of all 12 patients in Cohorts 1 and 2 in its...
Read ArticlePharmAust (PAA) completes the enrolment of the second cohort of patients in its phase one and two cl...
Read ArticlePharmAust (ASX:PAA) says it has completed enrolment of the second cohort of six patients in...
Read ArticlePatients from the first cohort treated with PharmAust’s lead drug monepantel under the Phase 1/2 Mot...
Read ArticleNoxopharm has developed a new product candidate based on mRNA technology IDT nabs TGA licence exten...
Read ArticlePharmAust (ASX:PAA) has announced a protocol deviation in its trial of Monepantel for treati...
Read ArticleIn PharmAust’s current Phase-2 study in the treatment of B-Cell Lymphoma in Canines with Monepantel...
Read ArticlePharmAust (PAA) claims a 12-year-old beagle in its clinical trial for the treatment of canine cancer...
Read ArticlePharmAust says it’s Phase-2 trial for the treatment of canine B-cell Lymphoma with Monepantel (MPL)...
Read ArticlePharmAust is looking to expedite the start of Phase-2 clinical trials of its lead drug monepantel fo...
Read ArticlePharmAust (ASX:PAA) says it will undertake an interim analysis of preliminary biomarkers and...
Read ArticleProtection of PharmAust’s intellectual property has hit a milestone with the impending grant of a ke...
Read ArticlePharmAust (PAA) is set to secure a European patent for the use of its Monepantel (MPL) product in co...
Read ArticlePharmAust (PAA) doses the first patient in the second cohort of its motor neurone disease (MND) tria...
Read ArticlePharmAust has dosed the first patient of the second cohort in its Phase 1/2 Motor Neurone Disease (M...
Read ArticlePharmAust has set up veterinary trial centres in Australia, New Zealand and the United States to eva...
Read ArticleThe FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have g...
Read ArticlePharmAust (ASX:PAA) has announced that the Trial Safety Committee has approved an escalation...
Read ArticlePharmAust (PAA) has received the green light from the trial safety committee to increase the tablet...
Read ArticleThe ASX will open flattish despite a selloff on Wall Street US jobless claims fell as the job marke...
Read ArticleJapanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based devic...
Read ArticlePharmAust (ASX:PAA) has announced that it had completed its first cohort of six patients in...
Read ArticlePharmAust (PAA) doses the first cohort of patients in its Phase 1/2 clinical trial of lead drug cand...
Read ArticlePharmAust is moving on to the next stage of its Phase 1/2 Motor Neurone Disease (MND) trial after it...
Read ArticleStock Insiders is a podcast series focussed on investing hosted by renowned business journalist Orie...
Read ArticleLeading Australian biotech company PharmAust has received recognition for its innovative clinical re...
Read ArticlePharmAust (PAA) completes enrolment of the first cohort of six motor neurone disease (MND) patientsT...
Read ArticlePharmAust (ASX: PAA) has enrolled the first patient cohort for its phase 1/2 clinical trial testing...
Read ArticleOwners of dogs participating in the MPL trial said they have seen an increase in the quality of life...
Read ArticleASX health stocks have been out of favour this year with rotation away from growth to value sector...
Read ArticleIt’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with...
Read ArticleClinical stage biotechnology company PharmAust’s (ASX: PAA) September quarter was highlighted by the...
Read ArticleWe take a look at how the 15 biotech IPOs that listed in 2021 are faring now Only two IPO stocks fr...
Read ArticleBlood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks...
Read ArticleAustralian biotechnology company PharmAust (ASX:PAA) has announced that the first patient ha...
Read ArticlePharmAust (PAA) doses its first patient in a phase one/two trial to test the effects of its monepant...
Read ArticleThe Phase 1/2 trial will study the safety and efficacy of PharmAust’s lead drug monepantel in treati...
Read ArticlePharmAust (ASX: PAA) has dosed the first patient of its phase 1/2 trial evaluating its lead drug mon...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has recruited the first canine with B-cell...
Read ArticleOngoing Phase 2 results from the study of Monepantel to treat canines with B cell lymphoma have been...
Read ArticlePharmAust (PAA) recruits the first pet dog with B cell lymphoma for its US canine phase two trialThe...
Read ArticlePharmAust’s ongoing trials on canine cancer have returned very encouraging results. The company has...
Read ArticleBiotech company PharmAust (PAA) reports “significant progress” on its canine cancer trials The comp...
Read ArticleThe latest results from PharmAust’s (ASX: PAA) canine trials have revealed that a combination of the...
Read ArticlePharmAust (ASX: PAA) could soon open the door to billion-dollar drug success opportunities after rec...
Read ArticlePharmAust’s clinical trials in canine cancers, human cancers, Covid-19 and MND/ASL could lead to mul...
Read ArticleWhat are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up...
Read ArticleUS FDA approves the first clinical trial using naturally derived psychedelic drugs It could open po...
Read ArticleIt’s quarterlies season as the ASX market announcements page becomes increasingly flooded with lodge...
Read ArticlePerth-based biotech PharmAust (ASX: PAA) has reported a June quarter heavily focused on the effects...
Read ArticlePharmAust subsidiary Epichem’s pilot agreement with Shell Australia was made possible by NERA, a non...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) wholly-owned subsidiary Epichem has been a...
Read ArticleA recent research reveals which biotech segments VCs are ploughing billions of dollars into We list...
Read ArticleWith the expansion of canine trials of its Monepantel treatment for B-cell lymphoma to the US in May...
Read ArticleFightMND’s annual Big Freeze event will be held during the AFL match between Collingwood and Melbour...
Read ArticleThe appointment of former Novartis exec Fiona Milner will provide PharmAust’s subsidiary Epichem the...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has appointed industry executive Fiona Mil...
Read ArticlePharmAust (ASX:PAA) is launching a Phase 1 clinical trial of monepantel for the treatment of...
Read ArticleBiotechnology company PharmAust (ASX: PAA) has updated the market on its range of clinical trials, l...
Read ArticlePharmAust (PAA) is facing delays for its phase one COVID-19 trial as it works to find a suitable si...
Read ArticlePharmAust will get early access to its FY22 R&D Tax Incentive amount, estimated at ~$210k, stren...
Read ArticlePharmAust (ASX:PAA) has announced the arrival of its cGMP grade monepantel tablets specifica...
Read ArticlePharmAust (ASX: PAA) is on track to start a clinical trial of its monepantel (MPL) drug in motor neu...
Read ArticleThe much anticipated Phase 1 clinical trial of PharmAust’s lead asset Monepantel on patients with Mo...
Read ArticlePharmAust (PAA) receives its first monepantel (MPL) tablets specifically designed for the Phase I m...
Read ArticleThe ASX 200 is set to open higher today, extending Friday’s 2% gain US Fed Chairman Jerome Powell h...
Read ArticlePharmAust (ASX:PAA) has announced an agreement with Pathway Vet Alliance dba as Thrive Pet H...
Read ArticleThe expansion of the canine trial of Monepantel to the US comes after successful earlier trials in b...
Read ArticlePharmAust’s (ASX: PAA) phase 2 trial evaluating its monepantel (MPL) drug in canines with B cell lym...
Read ArticlePharmAust (PAA) expands its Monepantel B Cell Lymphoma canine trial into the US The biotech company...
Read ArticleQuarterlies: A data dump of intrigue and a smidgen of smoke and mirrors. But while the pain is akin...
Read ArticlePharmAust (ASX: PAA) has announced the company is adequately funded to continue its current activiti...
Read ArticleThe Healthcare sector has been struggling as the pandemic wanes But most money managers are still b...
Read ArticleClinical stage biotechnology company PharmAust (ASX: PAA) has received a $708,000 research and tax d...
Read ArticleThe R&D refund provides PAA with timely cash support as it advances its exciting clinical trial...
Read ArticlePharmAust (PAA) receives a $708,000 research and development tax incentive refund The company says...
Read ArticleThe healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak mark...
Read ArticleThe much anticipated Phase 1 clinical trial of PharmAust’s lead asset monepantel on patients with Mo...
Read ArticleClinical-stage biotechnology company PharmAust (PAA) receives over $201,000 under the first instalm...
Read ArticleClinical-stage biotech PharmAust (ASX: PAA) is closer to starting its phase 1 clinical trial evaluat...
Read ArticleBiotech sector has had a tough time recently But there are signs of things improving this year A lo...
Read ArticlePharmAust says there’s a goldmine of unexplored data from companion animals’ cancer research – data...
Read ArticleThe recent super-toppy prices of Australia’s major commodity exports took a rare backward step today...
Read ArticleThe production of its own monepantel (MPL) drug means that PharmAust is now ready to commence human...
Read ArticlePharmAust (PAA) completes manufacturing of current good manufacturing practice (cGMP) grade drug mo...
Read ArticleASX to fall, Nasdaq shaves another 2% Wall Street was mainly lower overnight, as the tech heavy Nasd...
Read ArticleAustralian clinical-stage biotechnology company PharmAust (ASX: PAA) has commenced the manufacture o...
Read ArticleTelehealth was already a growing space even before the pandemic, but COVID had launched it into the...
Read ArticlePharmAust (ASX:PAA) has provided an update on the Walter and Eliza Hall Institute investigat...
Read ArticleThe WEHI study demonstrated that PharmAust’s lead drug monepantel can kill the HTLV-1 virus and inhi...
Read ArticleBiotech PharmAust (ASX: PAA) has demonstrated its lead drug monepantel (MPL) can kill the leukaemia...
Read ArticlePharmAust (PAA) receives evidence its monepantel (MPL) drug may inhibit the human T-cell leukaemia...
Read ArticlePharmAust’s appointment of UK-based Ergomed means that it’s now in a position to start on the COVID-...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has engaged UK-based Ergomed Clinical Rese...
Read ArticlePharmAust (PAA) has appointed Ergomed Clinical Research to commence COVID-19 clinical trials The tr...
Read ArticleThe ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial t...
Read ArticleAt the time of writing, the ASX 200 Health Index (XHJ) is up by over 4%, while the benchmark ASX 200...
Read ArticleEpichem’s successful e-waste project could create new revenue streams for PharmAust, as it eyes the...
Read ArticlePharmAust’s (PAA) subsidiary successfully completed the Oxidative Hydrothermal Dissolution (OHD) te...
Read ArticleThe S&P/ASX200 pared earlier losses to finish ~0.2% lower. Wall Street lifted, but my word — th...
Read ArticlePharmAust (PAA) announces manufacturing for monepantel is on track to meet the nominated clinical t...
Read ArticlePharmAust is passing all the tests and is on schedule to start its crucial Phase I/II trial of monep...
Read ArticlePharmAust’s clinical trials of monepantel in dog cancer, COVID-19 and motor neurone disease are all...
Read ArticleAt the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, be...
Read ArticleIt’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and...
Read ArticleThe life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, th...
Read ArticleThe renewal contract marks the 14th year of collaboration between PharmAust’s subsidiary Epichem and...
Read ArticlePharmAust’s clinical trials of monepantel in canines, COVID-19 and motor neurone disease are all exp...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 los...
Read ArticlePharmAust’s (PAA) upcoming human trials receives a major boost as the company’s GMP monepantel (MPL...
Read ArticleHighlights The new COVID-19 variant Omicron is gradually approaching many counties around the w...
Read ArticleIt’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 los...
Read ArticleThe Phase 1 human clinical trials of monepantel (MPL) for the treatment of COVID-19 and motor neuron...
Read ArticlePharmAust (PAA) sets a start date for its clinical trials for its lead drug candidate on patients w...
Read ArticleS&P 500 at record high again All three US stock market benchmarks were higher on Tuesday, bolste...
Read ArticlePharmAust (ASX:PAA) has signed agreements with Veterinary Specialists Auckland and Intuit Re...
Read ArticleThe ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index w...
Read ArticleThe expansion of PharmAust’s Phase 2b studies in New Zealand is the first step towards launching a P...
Read ArticleStockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) per...
Read ArticlePharmAust (PAA) signs agreements to expand its canine lymphoma studies into New Zealand A deal has...
Read ArticlePharmAust is conducting multiple studies on lead drug monepantel, as it looks to commercialise the d...
Read ArticleAfter completing MPL demonstration batch manufacture, PharmAust is now preparing for clinical trials...
Read ArticlePharmAust (PAA) has reached out to COVID-19 trial sites following production of a demonstration bat...
Read ArticleHighlights ASX 200 continued to trade in green on Tuesday despite losses in metals & mining...
Read ArticleHighlights Before COVID-19 struck, Australian families were spending over 10% of their weekly ho...
Read ArticlePharmAust (ASX:PAA) has provided an update on its Phase 2b trial testing the anti-cancer act...
Read ArticleHighlights Australian shares are expected to give away most of Monday’s gains after latest Chine...
Read ArticleAfter encouraging results from Phase 2 trials, PharmAust is now getting ready for a Phase 3 trial of...
Read ArticleIt’s been a busy morning for the ASX Healthcare sector, with plenty of positive announcements for in...
Read ArticleWall Street advances on strong earnings US stocks advanced on Friday on strong corporate earnings wh...
Read ArticleThe recent breakthrough in the US on antiviral molnupiravir has shone the spotlight on PharmAust’s o...
Read ArticleThe options offering will give loyal shareholders the opportunity to cash in on PharmAust’s success...
Read ArticleEpichem’s novel technology that converts waste to energy is a game changer, and will take the compan...
Read ArticleAlthough earnings results were the main theme in August, there were also some notable healthcare bre...
Read ArticlePharmAust is set to benefit from Epichem’s debt repayment with an expected improvement to the bottom...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 7...
Read ArticleSummary Emyria has signed a deal with the University of Western Australia (UWA) to develop a nov...
Read ArticleThe ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the...
Read ArticleThe completion of the flow reactor will potentially take PharmAust into the multi-billion dollar bio...
Read ArticleASX 200 health stocks index fell by 0.12% this morning, compared to the broader index which fell by...
Read ArticleWall Street mixed, Square jumps 10pc US stock markets were mixed overnight, as America’s top infecti...
Read ArticlePharmAust has had a busy and productive quarter, setting the foundations for the commercialisation o...
Read ArticleStockhead’s Q-Wrapz video series features one-on-one interviews showcasing the latest quarterly resu...
Read ArticleWhile the focus has been largely on vaccines, PharmAust is trialling a pill that directly targets SA...
Read ArticleSummary BHP Group (ASX:BHP) shares climb over 3% on Tesla nickel supply deal Adbri (ASX:ABC) si...
Read ArticleThe patent filing today is another step forward for PharmAust towards commercialisation of monepante...
Read ArticleSummary The S&P/ASX200 gained as much as 0.9%, crossing above its 20-day moving average. ...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has lodged a patent application for the us...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 7...
Read ArticleClinical-stage biotechnology company PharmAust (ASX:PAA) has executed a research services ag...
Read ArticleThe collaboration agreement today will expand PharmAust’s work on viruses and broaden the scope pote...
Read ArticlePharmAust (ASX: PAA) will evaluate the impact of its monepantel (MPL) drug on the human t-lymphotrop...
Read ArticleWall Street at fresh record highs All three key US benchmarks rose and reached fresh record highs on...
Read ArticleClinical-stage biotechnology company PharmAust (ASX:PAA) has announced that after formal tes...
Read ArticleIt’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52...
Read ArticleThe stability tests marks another key step on PharmAust’s path to commercialisation. Clinical oncolo...
Read ArticleClinical-stage biotechnology company PharmAust (ASX: PAA) has reported positive results from ongoing...
Read ArticleThe successful conclusion of its Phase II clinical trials has now opened the door to the Phase III s...
Read ArticlePharmAust Limited’s (ASX: PAA) clinical trials testing anti-cancer drug monepantel in canine lymphom...
Read ArticleS&P 500 closed at record high again Wall Street closed Friday mostly on a high note, with the S&...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has ret...
Read ArticleHealthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financia...
Read ArticleAfter securing ethics approval, PharmAust (ASX: PAA) is gearing up to begin a phase I clinical trial...
Read ArticleThe Phase I clinical trial of lead drug Monenpantel in humans is an exciting development after earli...
Read ArticlePharmAust (ASX:PAA) has announced it will proceed with a new phase one clinical trial to ass...
Read ArticleWall Street mixed, as iron ore and oil gain The US stock market finished mixed, with energy being th...
Read ArticleThe appointment of Dr Kim Agnew will support PharmaAust’s effort in its effort to progress to Phase...
Read ArticleClinical stage oncology company PharmAust (ASX: PAA) has appointed Dr Kim Agnew as the new principal...
Read ArticleThe federal government’s “patent box” initiative caught the eye of Australia’s biotech sector in Tue...
Read ArticleSummary Neuren Pharmaceuticals obtained a Canadian patent grant for trofinetide, with a patent t...
Read ArticlePharmAust (ASX:PAA) has announced it will be conducting a half-dozen clinical trials through the sec...
Read ArticleSix dogs have completed PharmAust’s (ASX: PAA) phase IIb trial evaluating its lead drug monepantel (...
Read ArticleSummary Oventus Medical witnessed growth in booked revenue and acceleration in telehealth bookin...
Read ArticleSummary Regenerative medicine player Orthocell has announced positive results from the US 510(k)...
Read ArticlePharmAust (ASX:PAA), a clinical-stage oncology company, has updated on an interim analysis o...
Read ArticleToday’s crucial milestone takes the company a step further towards commercialisation of its Monepant...
Read ArticleAn interim analysis of a phase IIb trial conducted by clinical-stage oncology company PharmAust (ASX...
Read ArticleClinical-stage oncology company PharmAust (ASX:PAA) has announced the receipt of over $750,0...
Read ArticleClinical-stage oncology company PharmAust (ASX: PAA) has received a hefty rebate from the Australian...
Read ArticleThe ASX closed upwards again and all sectors were in the green. The ASX 200 rose 0.61 per cent to 6,...
Read ArticleFurther pre-clinical testing of PharmAust’s (ASX: PAA) monepantel (MPL) and monepantel sulphone (MPL...
Read ArticleThe ASX picked up where it left off before the Easter break with another day of gains. The ASX 200 r...
Read ArticlePharmAust (ASX: PAA) has completed assessment of the first five dogs in a phase IIb trial of its ant...
Read ArticleSource: janews, Shutterstock Summary ASX-listed cannabis player Botanix Pharmaceuticals has obt...
Read ArticleEpichem, the subsidiary of ASX-listed PharmAust (ASX:PAA), has signed a licensing agreement with Ill...
Read ArticleSource: S_L, Shutterstock Summary Epichem has signed a license deal with Thermaquatica for the...
Read ArticlePharmAust’s (ASX: PAA) subsidiary Epichem has inked a licencing deal that will see it research, deve...
Read ArticleWall Street rallies led by tech Dow Jones and S&P 500 trimmed losses from the last few days, ris...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. It’s been a mixed two weeks f...
Read ArticleCOVID-19 vaccines have reached Australia but ASX stocks that were making anti-COVID 19 drugs or test...
Read ArticleBiotech company PharmAust (ASX: PAA) has officially begun recruitment for the phase IIb trial of its...
Read ArticleBiotechnology firm PharmAust (ASX: PAA) is looking to recruit more canines with B-cell lymphoma to a...
Read ArticleFollowing a successful phase IIa trial using monepantel (MPL) to treat canine lymphoma, PharmAust’s...
Read ArticleSummary Epichem, PharmAust’s wholly-owned subsidiary, has obtained WasteSorted e-Waste Grant wor...
Read ArticleIt’s been another positive day on the ASX in the wake of Democrats gaining control of the US Senate...
Read ArticleSummary PharmAust Ltd (ASX:PAA) announced that it is working closely with Leiden University Medi...
Read ArticleSummary PharmAust and the ONJCRI researchers to investigate cancer genomes in detail and match a...
Read ArticleASX large cap biotech Mesoblast (ASX:MSB) is not alone in fighting Acute Respiratory Distress Syndro...
Read ArticleOncology company PharmAust (ASX: PAA) has posted a strong quarter of business activity, led by a hef...
Read ArticleClinical-stage oncology company PharmAust (ASX: PAA) has announced the Olivia Newton-John Cancer Res...
Read ArticlePharmAust (ASX: PAA) is set to test the ability of its monepantel and monepantel sulfone drugs on th...
Read ArticleMotor neurone disease (MND) charity FightMND has awarded oncology company PharmAust (ASX: PAA) a gra...
Read ArticleHere’s our fortnightly wrap of all the news driving ASX health stocks. The health sector made a bit...
Read ArticleOncology company PharmAust (ASX: PAA) has provided a timely update to the market concerning developm...
Read ArticleOncology company PharmAust (ASX:PAA) will continue with the development of its Monepantel cancer tre...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleDetermined to become one of the first companies to develop an active treatment for COVID-19, oncolog...
Read ArticlePharmAust (ASX: PAA) subsidiary Epichem has entered into a 50:50 joint venture agreement with Wester...
Read ArticleOncology company PharmAust (ASX: PAA) has narrowed its losses for the full year as it celebrated man...
Read ArticlePreliminary research findings on PharmAust’s (ASX: PAA) lead candidates monepantel and monepantel su...
Read ArticleSomnoMed (ASX:SOM) is the latest Australian health company to look to Silicon Valley for its board,...
Read ArticleClinical stage oncology company PharmAust (ASX: PAA) has attributed a successful June quarter perfor...
Read ArticleNearly two years of pain for Factor Therapeutics (ASX:FTT) shareholders could be over soon with the...
Read ArticleThe PharmAust Limited (ASX: PAA) share price had an impressive run on the market today, finishing 2...
Read ArticleShares in PharmAust Ltd (ASX:PAA) opened at 15 cents on Thursday morning, representing a gain of nea...
Read ArticleA repeat preliminary evaluation of PharmAust’s (ASX: PAA) lead cancer drug monepantel and monepantel...
Read ArticleA Perth-based pharmaceutical company attempting to repurpose existing drugs for COVID-19 treatment h...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticlePreliminary clinical work by PharmAust (ASX: PAA) on the effects of its lead candidate monepantel an...
Read ArticleThe results of promising preliminary experiments by PharmAust Limited (ASX:PAA), indicating the supp...
Read ArticlePerth-based company PharmAust (ASX: PAA) has announced positive preliminary results in experiments a...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleToday, PharmAust Ltd [ASX:PAA] is the latest in a long list to add to the field of cancer treatment....
Read ArticleOncology company PharmAust (ASX: PAA) came out of a trading halt this morning with news that its mon...
Read ArticlePharmAust (ASX:PAA) shares surged this morning on news a clinical trial of its drug that fights canc...
Read ArticlePharmAust Ltd (ASX:PAA), a clinical-stage oncology company, has released promising data in relation...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleClinical stage oncology company PharmAust (ASX:PAA) has entered into a Materials Transfer Ag...
Read ArticlePharmAust Ltd’s (ASX:PAA) wholly owned subsidiary Epichem has produced its first batch of chemistry...
Read ArticleToday three more ASX small caps entered the fight against COVID-19 and all of them are notching shar...
Read ArticlePharmAust Limited (ASX:PAA) has entered into a Materials Transfer Agreement with the Walter and Eliz...
Read ArticleStockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade....
Read ArticleZelira Therapeutics (ASX:ZLD) chief Dr Richard Hopkins confirms what your columnist suspected was a...
Read ArticleSpecial Report: Cannabis products for pets is big business but just two ASX-listed companies are pay...
Read ArticlePharmAust (PAA) claims its business progressed “very successfully” in the 2019 December quarter Its...
Read ArticlePharmAust (PAA) has received a research and development tax refund of more than $700,000 from the A...
Read ArticleThe European Commission has granted Orphan drug status for Alterity Therapeutics’ (ASX:ATH) lead mol...
Read ArticlePharmAust’s (PAA) subsidiary, Epichem, has been awarded an extension to its long-term contract with...
Read ArticleGenetic Technologies (ASX:GTG) shares doubled this morning after the company confirmed the US launch...
Read ArticlePharmAust Limited’s (ASX:PAA) wholly-owned subsidiary, Epichem Pty Ltd, has been awarded an extensio...
Read ArticlePharmAust Ltd (ASX:PAA), a clinical-stage oncology company developing targeted cancer therapeutics f...
Read ArticleWho needs human companionship when we have pets? They’re loyal, always happy to see you and won’t di...
Read ArticleIt can be difficult to swallow banker-sized executive salaries in an earnest but yet-to-achieve smal...
Read ArticleClinical stage oncology company, PharmAust Ltd (ASX:PAA) has provided recruitment guidance for its a...
Read ArticleClinical-stage oncology company, PharmAust (ASX:PAA) has released its quarterly, highlighting the co...
Read ArticleClinical-stage oncology company, PharmaAust Ltd (ASX: PAA) has announced the appointment of Mr. Coli...
Read ArticlePharmAust (ASX: PAA), a clinical-stage oncology company, says it has received commitments to...
Read ArticleOn Stockhead today: are semiconductors about to pick up again, California’s first pot cafe opens, bi...
Read ArticleOn Stockhead today: Tim Treadgold on why gold miner Pantoro is a stock to watch, milk stocks in heal...
Read ArticleThe notion of ‘everything old is new again’ applies not just to fickle fashion trends, but to drug d...
Read ArticleOncology company PharmAust (ASX: PAA) is on the home straight to commencing a milestone drug trial f...
Read ArticlePharmAust (ASX:PAA), a clinical-stage oncology company, has announced the arrival of its GMP...
Read ArticleToday Rat's Rant joinsFinfeed as a regular contributor, to provide his irreverent analysis on what A...
Read ArticleSince the ASX is flooded with quarterlies, we’ve summarised a list of the five health companies that...
Read ArticleIn this week’s recap of substantial holders, Australian Super became an substantial holder in Gage R...
Read ArticlePerth-based PharmAust (ASX:PAA) has received ethics approval from the NSW Department of Prim...
Read ArticleThe below-mentioned healthcare stocks have provided significant returns in the last six months and h...
Read ArticlePharmAust (ASX:PAA), a clinical-stage oncology company, has announced its Perth-based synthe...
Read Article
Open an account with an online broker of your choice. If you do not have an existing broker, consider Vested Equities' A$9.50 flat fee platform.
Sign up now »Place your order however you wish. If you need advice on buying or selling, you should seek the assistance of a full service financial adviser experienced in small cap equities.
